Loading...

CRBP CORBUS PHARMACEUTICALS HOLDINGS INC US FDA Inspections 8-K Filing

CRBS

CRBP

CORBUS PHARMACEUTICALS HOLDINGS INC

(CRBP)

2025 8-K

Show Summary

Summary

Financial Statements

Management Change

Financial Results

Clinical Trial Update

Share Sale Plan

Financial Results

Stock Sale Plan

Presentation Update

Financial Results

Rule 10b5-1 Plan

Phase 1 Clinical Trial Data...

Equity Compensation Plan Ap...

Risk Factors Update

Financial Results

Amended Employment Agreements

Rule 10b5-1 Plans Adopted

Financial Results

Update on Investor Presenta...

Amendment Filing

Underwriting Agreement

Termination of Prospectus S...

Financial Update

Clinical Trial Data Announc...

Delisting Notice

Update of Presentation

Delisting Notice

Financial Results

Financial Results

Financial Results

Financial Results and Manag...

Appointment of Director

Exclusive License Agreement...

Delisting Notice

External Links:

Corbus Pharmaceuticals announced data from its Phase 1 clinical trial for SYS6002 (CRB-701) at the 2025 ASCO GU, showing promising safety and efficacy results in patients with metastatic urothelial cancer and other solid tumors, with 26 out of 38 participants evaluable for efficacy.

AI Assistant

CORBUS PHARMACEUTICALS HOLDINGS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.